Eric Venker Sells 218,041 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 218,041 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22. Following the transaction, the chief operating officer now directly owns 896,869 shares in the company, valued at $9,345,374.98. This trade represents a 19.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00.

Roivant Sciences Stock Up 1.1 %

ROIV stock opened at $10.56 on Friday. The business has a 50 day moving average price of $11.34 and a two-hundred day moving average price of $11.59. The company has a market cap of $7.69 billion, a price-to-earnings ratio of 1.87 and a beta of 1.25. Roivant Sciences Ltd. has a twelve month low of $9.76 and a twelve month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%. On average, equities research analysts anticipate that Roivant Sciences Ltd. will post -1.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ROIV. Nordea Investment Management AB lifted its position in shares of Roivant Sciences by 22.5% in the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock valued at $3,306,000 after buying an additional 52,031 shares during the last quarter. TOMS Capital Investment Management LP acquired a new stake in shares of Roivant Sciences in the third quarter valued at approximately $46,333,000. Barclays PLC lifted its position in shares of Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after buying an additional 75,609 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Roivant Sciences by 13.3% in the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock valued at $45,147,000 after buying an additional 458,601 shares during the last quarter. Finally, Retirement Systems of Alabama lifted its position in shares of Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after buying an additional 112,286 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Roivant Sciences has an average rating of “Buy” and a consensus price target of $18.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.